Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
21.44 USD | -0.21% | +0.05% | +123.00% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
- Stock Market
- Equities
- FUSN Stock
- News FUSN PHAR
- Wedbush Downgrades Fusion Pharmaceuticals to Neutral From Outperform on Heels of Announced Sale to AstraZeneca, Adjusts PT to $24 From $13